Another instance is in the treatment of Binge Eating Disorder
Secher A, Jelsing J, Baquero AF, Hecksher-Sorensen J, Cowley MA, Dalboge LS et al
Key takeaways TRIUMPH-4 is the first successful Phase 3 readout for retatrutide, reporting 28.7% mean body-weight reduction at 68 weeks on the 12 mg weekly dose (26.4% on 9 mg, 2.1% on placebo)
Single vs Quadruple Receptor Activation# Weight Loss Data# Critical caveat: Bioglutide achieved comparable weight loss to semaglutide in 13 weeks versus 68 weeks, which if sustained would represent dramatically superior efficacy
Nausea is also common as your body begins to adjust, and some people may experience vomiting, diarrhea, or abdominal pain soon after the first dose
Stopping abruptly can lead to rapid weight regain and loss of metabolic benefits